Viatris Inc. (VTRS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Canonsburg, PA, United States. El CEO actual es Scott Andrew Smith.
VTRS tiene fecha de IPO 1980-03-17, 32,000 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $16.02B.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania, that develops and distributes a diverse portfolio of prescription brand drugs, generic medications, complex generics, biosimilars, and active pharmaceutical ingredients across four geographic segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company operates across multiple therapeutic areas including noncommunicable and infectious diseases, oncology, immunology, endocrinology, and ophthalmology, offering medicines in various formats such as oral solids, injectables, and complex dosage forms. Viatris markets well-known pharmaceutical brands including Lyrica, Lipitor, EpiPen, Viagra, and Celebrex, along with biosimilar franchises such as Fulphila and SEMGLEE, distributing its products through a broad network of pharmaceutical wholesalers, retailers, specialty pharmacies, and e-commerce channels. Beyond medications, the company provides patient support services including diagnostic clinics, educational seminars, and digital health tools. The company maintains strategic partnerships with leading biotechnology firms to expand its innovative pipeline and global reach.
